Financial Contrast: SEI Investments (NASDAQ:SEIC) versus Dominari (NASDAQ:DOMH)

Dominari (NASDAQ:DOMH) and SEI Investments (NASDAQ:SEIC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Volatility & Risk

Dominari has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, SEI Investments has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.

Profitability

This table compares Dominari and SEI Investments’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dominari	-231.55%	-31.02%	-28.13%
SEI Investments	25.44%	23.25%	20.25%

Insider and Institutional Ownership

42.5% of Dominari shares are held by institutional investors. Comparatively, 70.6% of SEI Investments shares are held by institutional investors. 9.7% of Dominari shares are held by company insiders. Comparatively, 14.3% of SEI Investments shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Dominari and SEI Investments, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	0	0	0	0	N/A
SEI Investments	1	2	1	0	2.00

SEI Investments has a consensus price target of $71.50, suggesting a potential upside of 2.19%. Given SEI Investments’ higher probable upside, analysts plainly believe SEI Investments is more favorable than Dominari.

Earnings and Valuation

This table compares Dominari and SEI Investments”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$9.51 million	1.14	-$22.88 million	($4.64)	-0.39
SEI Investments	$1.99 billion	4.61	$462.26 million	$3.66	19.12

SEI Investments has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than SEI Investments, indicating that it is currently the more affordable of the two stocks.

Summary

SEI Investments beats Dominari on 13 of the 13 factors compared between the two stocks.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

About SEI Investments

SEI Investments Company is a publicly owned asset management holding company. Through its subsidiaries, the firm provides wealth management, retirement and investment solutions, asset management, asset administration, investment processing outsourcing solutions, financial services, and investment advisory services to its clients. It provides its services to private banks, independent financial advisers, institutional investors, investment managers, investment advisors, wealth management organizations, corporations, retirement scheme sponsors, not-for-profit organizations, hedge fund managers, registered investment advisers, independent broker-dealers, financial planners, life insurance agents, defined-benefit schemes, defined-contribution schemes, endowments, foundations, and board-designated fund, through its subsidiaries. Through its subsidiaries, the firm manages separate client-focused portfolios. It also launches and manages equity, fixed income, and balanced mutual funds, through its subsidiaries. Through its subsidiaries, the firm invests in public equity and fixed income markets. It employs fundamental and quantitative analysis with a focus on top-down and bottom-up analysis to make its investments, through its subsidiaries. SEI Investments Company was founded in 1968 and is based in Oaks, Pennsylvania.